Truist analyst Les Sulewski raised the firm’s price target on Collegium Pharmaceutical (COLL) to $48 from $45 and keeps a Buy rating on the shares. The company is reaping rewards from solid back-to-school sales and marketing efforts, which pushed Jornay PM to record revenue, the analyst tells investors in a research note. The outperformance, along with another beat for the pain portfolio, prompted the management to once again raise 2025 guidance across the board, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceuticals Reports Record Growth and Optimistic Outlook
- Collegium Pharmaceutical price target raised to $46 from $44 at H.C. Wainwright
- Collegium Pharmaceutical Reports Record Q3 2025 Results
- Collegium Pharmaceutical Reports Strong Q3 2025 Financial Results
- Collegium raises FY25 revenue view to $775M-$785M from $745M-$760M